Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.

Trial Profile

Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms RAPIDA
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 02 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top